Use access key #2 to skip to page content.
$71.91 -0.43 (-0.59%)
8/21/2008 4:00 PM

Celgene Corp (CELG)

CAPS Rating:
****

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CELG

Add Stock to Watchlist

What the Community Thinks

Total Members

1056 Outperforms
49 Underperforms
 

All-Stars

332 Outperforms
13 Underperforms
 

Wall Street

16 Outperforms
0 Underperforms
 

Members bullish on CELG are also bullish on:

Members bearish on CELG are also bearish on:

Ticker Tags

S&P 500 (480), Biotechnology (294), Large Cap (467), Drug Manufacturers - Major (27), Cancer Drugs (6), Nasdaq 100 (99)
Suggest a tag

Celgene Corp At A Glance

Current Price: $71.91
Last Trade Time: 8/21/2008 4:00 PM
Open: $72.11
Previous Close: $72.34
Daily Range: $70.75 - $72.27
52-Week Range: $41.26 - $77.39
Volume: 2,919,518
Market Cap: $32.91B
P/E Ratio: 74.12
Compare Our Special Broker Offers!

Stock Trends

CELG VS S&P 500 (SPY)

CELG 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for CELG

More Headlines...

Top Bull Pitch

Recs

1

Celgene Corp (CELG)

Avatar kfisherprotege (67.81) Submitted: 7/01/08 4:09 PM

Revlimid and Vidaza are both gaining market share. The latter, a bone marrow cancer drug, got a great boost by the failing results of rival dacogen from SuperGen. Vidaza is projected to gain about 2/3 of the market. Previously it had just 50%.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

7

Celgene Corp (CELG)

Avatar NetscribeBiotech (79.15) Submitted: 2/22/07 2:19 AM

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for ENL and multiple myeloma, Revlimid for myelodysplastic syndromes and multiple myeloma, Alkeran for mul...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 167 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (CELG)

Avatar udflyerz (93.10) Submitted: 8/16/08 6:26 PM : Outperform Start Price: $76.38 CELG Score: -3.84

saw this in Janus20 fund.... will watch it

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CELG)

Avatar Bungi82 (< 20) Submitted: 8/16/08 4:15 AM : Outperform Start Price: $76.38 CELG Score: -3.84

Excellent.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CELG)

Avatar jbeck111 (< 20) Submitted: 8/12/08 8:24 PM : Outperform Start Price: $74.61 CELG Score: -2.99

Well run, good research. Will continue to grow

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CELG)

Avatar nysegal (35.69) Submitted: 8/05/08 2:24 AM : Outperform Start Price: $74.00 CELG Score: -4.22

Earnings set to increase 45% in 08 and 51% in 09; stock is trading at 31x > earnings. In short-run could trade down to 64 or below so don't need to rush in. Have owned this issue for some time now and have trimmed back (and taken profits) when get to overweight in portfolio.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CELG)

Avatar westerntech (33.53) Submitted: 7/26/08 9:40 PM : Outperform Start Price: $72.16 CELG Score: -2.17

top drugs for bone marrow failure disease,multiple myeloma.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 167 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 16 of 16  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCreditSuiss 95.42 07/25/08 Outperform NS $74.45-3.41%+1.40%-4.82
TrackPacificGrow 91.99 05/09/08 Outperform NS $61.26+17.38%-8.10%+25.48
TrackWachovia 75.04 12/04/07 Outperform NS $60.12+19.61%-12.86%+32.47
TrackBofASec 97.33 11/26/07 Outperform NS $63.20+13.78%-11.51%+25.30
TrackBMOCapital 90.53 11/20/07 Outperform NS $64.87+10.85%-11.31%+22.16
TrackSwensen 55.92 09/30/07 Outperform NS $71.31+0.84%-16.24%+17.08 Toggle the visibility of 60-Second Pitch and replies
TrackWMBlair < 20 08/28/07 Outperform NS $60.00+19.85%-11.97%+31.82
TrackJefferies 95.48 07/12/07 Outperform NS $60.00+19.85%-16.13%+35.98
TrackLehmanBros 90.90 06/26/07 Outperform NS $57.26+25.59%-14.92%+40.50
TrackPiperJaff 77.67 04/05/07 Outperform NS $56.07+28.25%-11.03%+39.28
TrackBernstein 81.86 03/13/07 Outperform NS $51.37+39.98%-9.08%+49.06
TrackUBS 96.60 02/21/07 Outperform NS $53.70+33.91%-12.23%+46.14
TrackRodmanRen < 20 12/18/06 Outperform NS $58.75+22.40%-10.34%+32.74
TrackLazardCapit 84.82 11/20/06 Outperform NS $56.20+27.95%-8.76%+36.71
TrackJMP < 20 10/30/06 Outperform NS $48.59+47.99%-7.12%+55.12
TrackJimCramer 81.38 02/27/06 Outperform 3W $38.45+87.02%-1.59%+88.62

Results 1 - 16 of 16  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners